ORIGINAL ARTICLE
Comparison of mutation profile between primary phyllodes tumors of the
breast and their paired local recurrences
More details
Hide details
1
Department of Surgical Oncology, National Research Institute of Oncology, Kracow Branch, Krakow, Poland
2
Department of of Anatomy, Jagiellonian University Medical College, Krakow, Poland
3
Department of Tumour Pathology, National Research Institute of Oncology, Krakow Branch, Krakow, Poland
4
Department of Molecular Diagnostics, Holycross Cancer Center, Kielce, Poland
5
Division of Medical Biology, Institute of Biology Jan Kochanowski University, Kielce, Poland
6
Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland
7
Department Laboratory of Molecular Diagnostics, Cytogenetics and Flow Cytometry Specialist Hospital in Brzozow, Poland
Publication date: 2020-05-20
Pol J Pathol 2020;71(1):7-12
KEYWORDS
ABSTRACT
Phyllodes tumor of the breast (PTB) is a rare neoplasm and accounts for 0.2-2.0% of breast cancer in women. Histopathological diagnosis of the tumor is difficult, and histological features do not always predict the course of the disease and the risk of progression. Pathogenesis and molecular biological characteristics as well as PTB prognostic factors are unknown. In search for genetic factors affecting PTB progression, 10 patients were analyzed for whom material from the primary tumor and local recurrence was available. DNA isolated from paraffin blocks was sequenced using the next-generation sequencing method (NGS). In 4 pairs, consisting of primary tumor and local recurrence, probably pathogenic/pathogenic variants were detected, and in three pairs they were observed in the CDKN2A gene, while other variants were found in PTEN and TP53 genes. NGS results indicate that the above-mentioned variants are hereditary, which suggests that the CDKN2A gene might be involved in cancerogenesis of PTB. Additionally, the selected pathogenic variant of EGFR gene was exclusively detected in one recuurent tumor, which might suggest the involvement of this gene in the mechanism of progression. In order to determine if this variant is associated with progression, the frequency of this mutation should be examined in larger group of malignant and borderline tumors.
REFERENCES (14)
1.
Tan BY, Acs G, Apple SK, et al. Phyllodes tumours of the breast: a consensus review. Histopathology 2016; 68: 5-21.
2.
Hoon Tan P, Ellis I, Allison K, et al. The 2019 WHO classification of tumours of the breast. Histopathology 2020.
3.
Tan PH, Thike AA, Tan WJ, et al. Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. J Clin Pathol 2012; 65: 69-76.
4.
Mitus JW, Blecharz P, Jakubowicz J, et al. Phyllodes tumors of the breast. The treatment results for 340 patients from a single cancer centre. Breast 2019; 43: 85-90.
5.
Mitus JW, Blecharz P, Wysocki W. The appropriate width of the tumour-free margin in surgery of phyllodes tumour of the breast. Oncology and Radiotherapy 2019; 1: 013-014.
6.
Mitus JW, Blecharz P, Reinfuss M, et al. Changes in the clinical characteristics, treatment options, and therapy outcomes in patients with phyllodes tumor of the breast during 55 years of experience. Med Sci Monit 2013; 19: 1183-1187.
7.
Tremblay-LeMay R, Hogue JC, Provencher L, et al. How Wide Should Margins Be for Phyllodes Tumors of the Breast? Breast J 2017; 23: 315-322.
8.
Yom CK, Han W, Kim SW, et al. Reappraisal of conventional risk stratification for local recurrence based on clinical outcomes in 285 resected phyllodes tumors of the breast. Ann Surg Oncol 2015; 22: 2912-2918.
9.
Mitus JW, Blecharz P, Walasek T, et al. Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast. World J Surg 2016; 40: 323-328.
10.
Chaney AW, Pollack A, McNeese MD, et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer 2000; 89: 1502-1511.
11.
Mitus JW, Jakubowicz J, Walasek T, et al. Are patients with phyllodes tumor of the breast good candidates for breast conserving therapy? A single center experience. Eur J Gynaecol Oncol 2018; 39: 641-644.
12.
Nozad S, Sheehan CE, Gay LM, et al. Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Res Treat 2017; 162: 597-602.
13.
Tan WJ, Lai JC, Thike AA, et al. Novel genetic aberrations in breast phyllodes tumours: comparison between prognostically distinct groups. Breast Cancer Res Treat 2014; 145: 635-645.
14.
Liu SY, Joseph NM, Ravindranathan A, et al. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity. Mod Pathol 2016; 29: 1012-1027.